RMD

ResMed
D

RMD

Arincen97/100B

ResMed free cash flow 1993–2027

ResMed's free cash flow in Q1 FY2027, the three months to 30 September 2026, was 373.68M USD, down 9.8% on the same quarter a year before. ResMed's free cash flow over the last twelve months was 2.85B USD, up 61.2% on the twelve months before. In fiscal year 2026 it was 1.65B USD, down 0.7% on the year before.

Last updated 6 Nov 2026 · Next report 28 Jan 2027

Free cash flow

Free cash flow · +13.1% a year over 10 yearsFree cash flow margin

Growth

Fiscal yearPeriod endingFree cash flowGrowthFree cash flow marginOperating cash flowCapital expenditureFree cash flow per share
TTM30 Sept 20262.85B+61.21%49.70%3.12B-273.23M19.56
FY202630 Jun 20261.65B-0.73%29.18%1.81B-156.29M11.38
FY202530 Jun 20251.66B+29.18%32.29%1.75B-89.87M11.28
FY202430 Jun 20241.29B+130.00%27.46%1.40B-114.86M8.72
FY202330 Jun 2023559.30M+186.66%13.24%693.30M-134.00M3.79
FY202230 Jun 2022195.11M-68.53%5.45%351.15M-156.04M1.33
FY202130 Jun 2021619.89M-10.98%19.39%736.72M-116.83M4.23
FY202030 Jun 2020696.32M+82.42%23.55%802.26M-105.94M4.78
FY201930 Jun 2019381.71M-11.96%14.64%459.05M-77.34M2.64
FY201830 Jun 2018433.57M+26.56%18.53%505.03M-71.46M3.01
FY201730 Jun 2017342.58M-28.65%16.58%414.05M-71.48M2.40
FY201630 Jun 2016480.10M+54.26%26.11%547.93M-67.83M3.39
FY201530 Jun 2015311.24M+0.36%18.54%383.18M-71.94M2.18
FY201430 Jun 2014310.11M-6.32%19.94%391.27M-81.16M2.15
FY201330 Jun 2013331.04M+2.79%21.86%402.82M-71.78M2.26
FY201230 Jun 2012322.05M+54.69%23.53%383.16M-61.11M2.16
FY201130 Jun 2011208.19M+64.49%16.75%283.19M-75.00M1.32
FY201030 Jun 2010126.57M+1.54%11.59%188.21M-61.64M0.82
FY200930 Jun 2009124.66M+100.88%13.54%238.88M-114.22M0.81
FY200830 Jun 200862.06M+357.99%7.43%137.84M-75.78M0.39
FY200730 Jun 200713.55M—1.89%91.11M-77.56M0.09
FY200630 Jun 2006-3.72M-111.85%-0.61%99.03M-102.75M-0.02
FY200530 Jun 200531.39M+62.67%7.38%71.08M-39.69M0.21
FY200430 Jun 200419.30M-42.66%5.69%76.54M-57.25M0.14
FY200330 Jun 200333.65M+351.36%12.30%59.28M-25.64M0.24
FY200230 Jun 20027.46M+261.72%3.65%35.64M-28.19M0.05
FY200130 Jun 20012.06M-49.82%1.33%29.52M-27.46M0.02
FY200030 Jun 20004.11M—3.55%20.28M-16.17M0.03
FY199930 Jun 1999-4.30M—-4.85%18.20M-22.50M-0.03
FY199830 Jun 1998-5.00M-190.91%-7.52%6.80M-11.80M-0.04
FY199730 Jun 19975.50M+175.00%11.18%9.50M-4.00M0.05
FY199630 Jun 19962.00M—5.78%3.50M-1.50M0.02
FY199530 Jun 1995-1.10M-184.62%-4.68%700.00K-1.80M-0.02
FY199430 Jun 19941.30M+85.71%9.35%1.60M-300.00K0.02
FY199330 Jun 1993700.00K—9.09%1.00M-300.00K0.01

Figures in USD. Free cash flow is operating cash flow less capital expenditure. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

See also:Revenue,Net income,EPS,Shares outstanding,Operating income,Cash on hand,Total debt,Stock buybacks,Cash flow

Common questions about ResMed's free cash flow

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.